<SEC-DOCUMENT>0000950170-24-073771.txt : 20240614
<SEC-HEADER>0000950170-24-073771.hdr.sgml : 20240614
<ACCEPTANCE-DATETIME>20240614170007
ACCESSION NUMBER:		0000950170-24-073771
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240613
FILED AS OF DATE:		20240614
DATE AS OF CHANGE:		20240614

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Little Paul Sean
		CENTRAL INDEX KEY:			0001749385
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36620
		FILM NUMBER:		241045726

	MAIL ADDRESS:	
		STREET 1:		SIENTRA, INC.
		STREET 2:		420 SOUTH FAIRVIEW AVENUE, SUITE 200
		CITY:			SANTA BARBARA
		STATE:			CA
		ZIP:			93117

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eledon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-06-13</periodOfReport>

    <issuer>
        <issuerCik>0001404281</issuerCik>
        <issuerName>Eledon Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>ELDN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001749385</rptOwnerCik>
            <rptOwnerName>Little Paul Sean</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ELEDON PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>19800 MACARTHUR BLVD STE. 250</rptOwnerStreet2>
            <rptOwnerCity>IRVINE</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92612</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>Chief Financial Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.30</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2024-06-13</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>267470</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-05-01</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>267470</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>267470</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">This transaction represents the attainment of the performance conditions applicable to an option award subject to both performance-based and time-based vesting criteria granted to the reporting person on May 1, 2023. The option was determined to satisfy the performance-based vesting criteria with respect to 267,470 shares of underlying Common Stock on June 13, 2024 and time-based vesting criteria with respect to 66,867 shares of underlying Common Stock on May 1, 2024. The option will satisfy the time-based vesting criteria with respect to the 200,603 remaining shares of Common Stock underlying the option in substantially equal quarterly installments over a three-year period ending May 1, 2027.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Paul Little.</signatureName>
        <signatureDate>2024-06-14</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
